Alasdair Bamford

ORCID: 0000-0003-4764-229X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Kawasaki Disease and Coronary Complications
  • SARS-CoV-2 and COVID-19 Research
  • Pneumonia and Respiratory Infections
  • Cytomegalovirus and herpesvirus research
  • HIV-related health complications and treatments
  • Respiratory viral infections research
  • Long-Term Effects of COVID-19
  • Immunodeficiency and Autoimmune Disorders
  • Adolescent and Pediatric Healthcare
  • Tuberculosis Research and Epidemiology
  • Pharmaceutical studies and practices
  • Antibiotic Use and Resistance
  • Herpesvirus Infections and Treatments
  • Mechanical Circulatory Support Devices
  • interferon and immune responses
  • Antibiotics Pharmacokinetics and Efficacy
  • COVID-19 Impact on Reproduction
  • HIV, Drug Use, Sexual Risk
  • COVID-19 and healthcare impacts
  • Immune Cell Function and Interaction

Great Ormond Street Hospital
2016-2025

University College London
2016-2025

Great Ormond Street Hospital for Children NHS Foundation Trust
2014-2025

Medical Research Council
2021-2025

MRC Clinical Trials Unit at UCL
2018-2025

University of Bristol
2021-2024

University Hospitals Birmingham NHS Foundation Trust
2021-2024

University Hospitals Bristol NHS Foundation Trust
2024

Bristol Royal Hospital for Children
2024

University Hospitals Bristol and Weston NHS Foundation Trust
2024

Neurological manifestations have been reported in adults with coronavirus disease 2019 (COVID-19), which is caused by the highly pathogenic virus severe acute respiratory syndrome 2 (SARS-CoV-2).To report neurological of children COVID-19.In this case-series study, patients younger than 18 years who presented SARS-CoV-2 infection and symptoms to Great Ormond Street Hospital for Children (London, UK) between March 1, 2020, May 8, were included after was confirmed either a quantitative reverse...

10.1001/jamaneurol.2020.2687 article EN JAMA Neurology 2020-07-01
Yingfen Hsia Brian Lee Ann Versporten Yonghong Yang Julia Bielicki and 95 more Charlotte Jackson Jason G. Newland Herman Goossens Nicola Magrini Mike Sharland Adam Irwin Akhila Akula Alasdair Bamford Amanda Chang Andre da Silva Andrew Whitelaw Angela Dramowski Anil Vasudevan Anita Sharma Antonio José Justicia-Grande Ashok Chikkappa Barbara Slowinska-Jarzabek Bianca Rippberger Changan Zhao Chiara Tersigni Ching‐Lan Cheng Christian Harkensee Chuamei Jing Chunmei Zhu Chunyan Li Claudia Tagliabue Cristina Epalza Daglish Jacqueline Daiyin Tian Dasaratha Ramaiah Jinka Despoina Gkentzi Dhanya Dharmapalan Dona Benadof Eleni Papadimitriou Εlias Iosifidis Emmanuel Roilides Erbu Yarcı Ewa Majda-Stanisławska Ewelina Gowin Faye Chappell Federico Martinón‐Torres Francis Collett-White Gang Liu Gen Lu George A. Syrogiannopoulos Georgia Pitsava Gerardo Alvarez‐Uria Hana Renk Hana Mahmood Harri Saxén Heather Finlayson Helen Green Helena Rabie Hemasree Kandraju Hong Zhang Ita B. Okokon Jack Cross Jethro Herberg Jianping Li Jiaosheng Zhang Jikui Deng Jing Liu Jing Qian Jinhong Yang Joanna Sicińska Johannes Hübner Kahoru Fukuoka Kaihu Yao Ka Man Cheung Karla Ojeda Katerina Kaffe Katharina Kreitmeyer Katja Doerholt Keith Grimwood Kirsty Ledoare Konstantinos Vazouras Kunling Shen Lanfang Tang Lehai Zhang Li Lin Liat Ashkenazi‐Hoffnung Lijuan Wu Lijun Wang Lilian Teston Luisa Galli Lynne Speirs Μαρία Τσολιά Markus Hufnagel Markus Knuf Marzia Duse Mingjie Ding Mojca Rožič Mueller Premru Natasha O’Connell Nikolaus Rieber

Improving the quality of hospital antibiotic use is a major goal WHO's global action plan to combat antimicrobial resistance. The WHO Essential Medicines List Access, Watch, and Reserve (AWaRe) classification could facilitate simple stewardship interventions that are widely applicable globally. We aimed present data on patterns paediatric AWaRe be used for local national interventions.1-day point prevalence survey prescription were combined from two independent networks: Global Antimicrobial...

10.1016/s2214-109x(19)30071-3 article EN cc-by-nc-nd The Lancet Global Health 2019-06-11

Abstract Background The European AIDS Clinical Society (EACS) Guidelines were revised in 2021 for the 17th time with updates on all aspects of HIV care. Key points update Version 11.0 recommend six first‐line treatment options antiretroviral (ART)‐naïve adults: tenofovir‐based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine dolutegravir; dual therapy lamivudine emtricitabine dolutegravir. Recommendations preferred and alternative combinations from birth to...

10.1111/hiv.13268 article EN HIV Medicine 2022-03-25

Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care updated. Key Points Guidelines Update Version 12.0 recommend same six first‐line treatment options antiretroviral (ART)‐naïve adults as versions 11.0 11.1: tenofovir‐based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine dolutegravir; dual therapy with lamivudine emtricitabine dolutegravir. long‐acting section has been...

10.1111/hiv.13542 article EN cc-by-nc HIV Medicine 2023-10-18

Remdesivir shortens time to recovery in adults with severe coronavirus disease 2019 (COVID-19), but its efficacy and safety children are unknown. We describe outcomes COVID-19 treated remdesivir.Seventy-seven hospitalized patients <18 years old confirmed acute respiratory syndrome 2 infection received remdesivir through a compassionate-use program between March 21 April 22, 2020. The intended treatment course was 10 days (200 mg on day 1 100 daily subsequently for ≥40 kg 5 mg/kg 2.5 <40 kg,...

10.1542/peds.2020-047803 article EN PEDIATRICS 2021-04-21

The optimal dose and duration of oral amoxicillin for children with community-acquired pneumonia (CAP) are unclear.To determine whether lower-dose is noninferior to higher 3-day treatment 7 days.Multicenter, randomized, 2 × factorial noninferiority trial enrolling 824 children, aged 6 months older, clinically diagnosed CAP, treated on discharge from emergency departments inpatient wards 28 hospitals in the UK 1 Ireland between February 2017 April 2019, last visit May 21, 2019.Children were...

10.1001/jama.2021.17843 article EN JAMA 2021-11-02

BackgroundPaediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as in children (MIS-C) emerged April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess effect of intravenous immunoglobulin or corticosteroids compared usual care on duration hospital stay for PIMS-TS and compare tocilizumab (anti-IL-6 receptor monoclonal antibody) anakinra (anti-IL-1 antagonist) those inflammation refractory initial treatment.MethodsWe...

10.1016/s2352-4642(23)00316-4 article EN cc-by The Lancet Child & Adolescent Health 2024-01-22

ODYSSEY showed superior efficacy for dolutegravir-based antiretroviral therapy (ART) versus standard of care (SOC) in children living with HIV starting first-line or second-line ART aged 4 weeks older. Here, we aim to compare virological outcomes and resistance the dolutegravir group SOC up 96 weeks. was an open-label, multicentre, randomised, non-inferiority trial done 29 centres seven countries (Germany, Spain, South Africa, Thailand, UK, Uganda, Zimbabwe). recruited at least 28 days...

10.1016/s2352-3018(24)00155-3 article EN cc-by The Lancet HIV 2025-02-01

The 2015 Paediatric E uropean Network for Treatment of AIDS ( PENTA ) guidelines provide practical recommendations on the management HIV ‐1 infection in children urope and are an update to those published 2009. Aims treatment have progressed significantly over last decade, moving far beyond limitation short‐term morbidity mortality optimizing health status adult life minimizing impact chronic immune system development general. Additionally, there is a greater need increased awareness...

10.1111/hiv.12217 article EN cc-by-nc HIV Medicine 2015-02-03

The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management women living with human immunodeficiency virus (HIV) UK during pregnancy postpartum, their infants. scope includes use antiretroviral therapy (ART) both prevent vertical transmission HIV for welfare woman her baby, mode delivery recommendations specific patient populations where other factors need be taken into consideration, such as co-infection agents. are aimed at...

10.1111/hiv.12720 article EN HIV Medicine 2019-03-01

During autumn/winter 2022, UK pediatricians reported an unseasonal increase in invasive group A streptococcal infections; a striking proportion presenting with pneumonia parapneumonic effusion.

10.1097/inf.0000000000004418 article EN cc-by The Pediatric Infectious Disease Journal 2024-06-20

<h3>Background</h3> The value of interferon-γ release assays (IGRA) to diagnose active tuberculosis (TB) in children is not established, but these are being widely used for this purpose. authors examined the sensitivity commercially available IGRA TB UK compared with tuberculin skin test (TST). <h3>Methods</h3> established a paediatric network and conducted retrospective analysis data from investigated at six large centres. All centres had TST least one (T-Spot.TB or Quantiferon-Gold Tube)...

10.1136/adc.2009.169805 article EN Archives of Disease in Childhood 2009-10-08

Paediatric HIV disease is now, in the era of highly effective antiretroviral therapy (HAART), a chronic treatable disease, yet across Europe significant and death still occur despite apparent immune reconstitution, much this attributable to vaccine-preventable disease. The complexities HIV-associated immunocompromise paediatric age range, profile time-course reconstitution produced by HAART initiated at various ages stages are poorly characterized. Available data point multiple causative...

10.1111/j.1468-1293.2011.00982.x article EN HIV Medicine 2012-02-02
Coming Soon ...